Says Bilchick, This study adds to our knowledge of the effect of these GLP-1 receptor agonists on reducing morbidity, mortality, and now, in this large study, reducing incident atrial fibrillation over the long term. More research is still needed, especially regarding how different GLP-1 medications, doses, and treatment durations affect weight loss, inflammation, glucose control, Afib risk, and long-term cardiovascular health
Dietary composition can also influence sweating
Who should not use GH peptides Contraindications are not edge cases
Conflating them in clinical decision-making is a category error different peptides, different receptors, different indications
Publisher Responsibility: The publisher of this article has made every effort to ensure accuracy at the time of publication based on preclinical research, company-provided information, and publicly available data